Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

Fig. 3

PI3Kα/δ inhibitor promotes and sustain strong pro-inflammatory responses in CT-26 treated tumors. a Schematic of dosing and sample collection. b Heat map analysis of 268 differential gene expression between control and treated groups. c Top canonical pathways regulated at day 7 and day 14 after implant. d List of top upstream regulator ordered by p values and annotated for activation prediction. e Quantification of immune cellular subtypes based on RNAseq gene signatures within control and AZD8835 treated samples. f Quantification of immune cellular subtypes based on gene signatures between control and AZD8835 treated samples at 7 and 14 days time points. Statistical significance is indicated as p values, n = 6/group

Back to article page